ed in the highly selective National Medicine Catalog of
the National Medical Insurance Program. Tianyin owns and operates two GMP
manufacturing facilities and an R&D platform supported by leading Chinese
academic institutions. The Company has a pipeline of 47 pharmaceutical
products pending approval. Tianyin has an extensive nationwide distribution
network throughout China with a sales force of 720 salespeople. Tianyin is
headquartered in Chengdu, Sichuan Province with two manufacturing facilities
and a total of 1,365 employees. Tianyin achieved revenue of approximately
$33.5 million and net income of approximately $6 million in FY2008 ending June
30, 2008. For more information about Tianyin, please visit
http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company's filings with the
Securities and Exchange Commission.
For more information, please contact:
For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
China
Tel: +86-158-2122-5642
Email: Allen.y.tang@gmail.com
Investors:
Mr. Matthew Hayden, HC International
Tel: +1-561-245-5155
Email: matt.hayden@hcinternational.net
Web: http://www.hcinternational.net
'/>"/>SOURCE Tianyin Pharmaceutical, Co., Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
Tianyin Pharmaceutical Co., Inc. Series A Preferred Shareholders Approved Cash Dividend to Common Stockholders2.
Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders3.
Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results4.
Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program5.
Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST6.
Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program7.
Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets8.
Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction9.
Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets10.
Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake11.
Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors